TP53 and breast cancer: The increased MDM2 expression, caused primarily by gene amplification, is also observed in breast cancer, contributing to tumorigenicity via suppressing p53 function.58 They further implicated that the MDM2 amplification may serve as an adverse prognostic parameter only in ER+ early-stage breast cancer.